| Literature DB >> 9693282 |
T Fukuda1, T Kimiya, M Takahashi, Y Arakawa, Y Ami, Y Suzaki, S Naito, A Horino, N Nagata, S Satoh, F Gondaira, J Sugiyama, Y Nakano, M Mori, S Nishinohara, K Komuro, T Uchida.
Abstract
We have previously reported that purified Shiga-like toxins (SLT), SLT-I and SLT-II coupled with liposomes induced a substantial amount of anti-SLT-I and anti-SLT-II IgG antibody production, respectively, in mice. The levels of anti-SLT antibody in the sera of SLT-liposome-immune mice correlated well with the protection against subsequent challenge with SLT. In this study, mice were immunized intraperitoneally with the mixture of SLT-I-liposome and SLT-II-liposome and protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 was evaluated. All of the mice that received immunization with the mixture of SLT-I-liposome and SLT-II-liposome were protected against subsequent intravenous challenge with 10 LD50 of either SLT-I or SLT-II. Eight weeks after primary immunization, mice were inoculated intragastrically with 10(9) CFU of E. coli O157:H7 strain 96-60. All SLT-liposome-immune mice tested survived without any apparent symptom while control mice died within 5 days. In addition, as shown by other antigen-liposome conjugates, SLT-liposome induced undetectable anti-SLT IgE antibody production while they induced substantial amounts of anti-SLT IgG antibodies. These results suggest that SLT-liposome conjugate may serve as a candidate vaccine that induces protection against cytotoxin-producing E. coli infection.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9693282 DOI: 10.1159/000023961
Source DB: PubMed Journal: Int Arch Allergy Immunol ISSN: 1018-2438 Impact factor: 2.749